Project: Development of next-generation treatment for allergies: targeted glycan-allergen immunotherapy

The TARGIT project will develop a next-generation allergy vaccine to treat grass-pollen induced allergic rhinitis and asthma effectively and life-long. The vaccine is based on unique glycans, covalently linked to clinically relevant grass pollen derived peptides. We will generate Proof-of-Concept for the product, entering clinical testing with the large pharma partner Allergopharma directly after this project, as well as for the core technology providing direct spin-off towards other allergens.

Acronym TARGIT (Reference Number: 10545)
Duration 01/11/2016 - 01/11/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner